Circulating insulin-like growth factor-I and benign prostatic hyperplasia: A prospective study

Scandinavian Journal of Urology and Nephrology

Volumn 35, Issue 2, 2001, Pages 122-126

  Stattin, Pär ^a   Kaaks, Rudolf ^b   Riboli, Elio ^b   Ferrari, Pietro ^b   Dechaud, Henry ^c   Hallmans, Göran ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c Hopital de l'Antiquaille   (France)

Author keywords

Benign prostatic hyperplasia; Insulin like growth factor I; Plasma

Indexed keywords

INSULIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SWEDEN; TISSUE DISTRIBUTION;

HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; RISK;

EID: 0035008587     PISSN: 00365599     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655901750170506     Document Type: Article

References (26)

1. 1. Sagnier PP, Girman CJ, Garraway M, et al. International comparison of the community prevalence of symptoms of prostatism in four countries. Eur Urol 1996; 29: 15-20.
2. 2. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469-71.
3. 3. Giovannucci E, Rimm EB, Chute CG, et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol 1994; 140: 989-1002.
4. 4. Holtgrewe HL. Economic issues and the management of benign prostatic hyperplasia. Urology 1995; 46: 23-5.
5. 5. Lee C, Kozlowski JM, Grayhack JT. Etiology of benign prostatic hyperplasia. Urol Clin N Am 1995; 22: 237-46.
6. 6. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996; 88: 1118-26.
7. 7. Peehl DM, Cohen P, Rosenfeld RG. The role of insulin-like growth factors in prostate biology. J Androl 1996; 17: 2-4.
8. 8. Torring N, Vinter-Jensen L, Pedersen SB, Sorensen FB, Flyvbjerg A, Nexo E. Systemic administration of insulin-like growth factor I (IGF-I) causes growth of the rat prostate. J Urol 1997; 158: 222-7.
9. 9. Colao AM, Marzullo P, Spiezia S, et al. Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: An ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects. J Clin Endocrinol Metab 1999; 84: 1986-99.
10. 10. Colao A, Marzullo P, Ferone D, et al. Prostatic hyperplasia: an unknown feature of acromegaly. J Clin Endocrinol Metab 1998; 83: 775-9.
11. 11. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997; 76: 1115-8.
12. 12. Ketelslegers JM, Maiter D, Maes M, Underwood LE, Thissen JP. Nutritional regulation of the growth hormone and insulin-like growth factor-binding proteins. Horm Res 1996; 45: 252-7.
13. 13. Weinehall L. Umeå University Medical Dissertations. ISSN 0346-6612 and ISBN 91-7191-388-2. Umeå: Umeå University, 1997.
14. 14. Tunstall Pedoe H. The world health organization MONICA project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. J Clin Epidemiol 1988; 41: 105-14.
15. 15. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563-6.
16. 16. Wolk A, Mantzoros CS, Andersson SO, et al. Insulin-like growth factor I and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998; 90: 911-5.
17. 17. Masumori N, Tsukamoto T, Kumamoto Y, et al. Japanese men have smaller prostate volumes but comparable urinary flow rates relative to American men: results of community based studies in 2 countries [see comments]. J Urol 1996; 155: 1324-7.
18. 18. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3-34.
19. 19. Oh Y, Muller HL, Lamson G, Rosenfeld RG. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem 1993; 268: 14964-71.
20. 20. Nickerson T, Pollak M, Huynh H. Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2, 3, 4 and 5. Endocrinology 1998; 139: 807-10.
21. 21. Stewart CE, Rotwein P. Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiol Rev 1996; 76: 1005-26.
22. 22. Nyomba BL, Berard L, Murphy LJ. Free insulin-like growth factor I (IGF-I) in healthy subjects: relationship with IGF-binding proteins and insulin sensitivity. J Clin Endocrinol Metab 1997; 82: 2177-81.
23. 23. Hammarsten J, Högstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 1999; 8: 29-36.
24. 24. Goodman-Gruen D, Barrett-Connor E. Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study. Am J Epidemiol 1997; 145: 970-6.
25. 25. Muti P, Trevisan M, Micheli A, et al. Reliability of serum hormones in premenopausal and postmenopausal women over a one-year period. Cancer Epidemiol Biomarkers Prev 1996; 5: 917-22.
26. 26. de Klerk NH, English DR, Armstrong BK. A review of the effects of random measurement error on relative risk estimates in epidemiological studies. Int J Epidemiol 1989; 18: 705-12.